阿立哌唑和奥氮平治疗精神分裂症的效果、血糖及血脂代谢的比较

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (650 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the curative effect, blood glucose and blood lipid metabolism of Aripiprazole and Olanzapine in the treatmen oft patients with schizophrenia. Methods From January 2016 to June 2017, 78 cases of patients with schizophrenia in the First Affiliated Hospital of Xinjiang Medical University were selected as research objects and divided into Aripiprazole group and Olanzapine group by random number table, with 39 cases in each group. The Aripiprazole group was given Aripiprazole with 10-30 mg/d and the Olanzapine group was given Olanzapine with 5-20 mg/d. Both groups were treated for 6 weeks. The positive and negative symptom scale was used to evaluate the curative effect before and after treatment. The blood biochemical index, body mass index(BMI) and the incidence of adverse reactions were compared between the two groups. Results The curative effect in the Aripiprazole group (84.62%) was higher than that of Olanzapine group (82.05%), but with no statistically significant difference (P ＞ 0.05). After treatment, the blood glucose level, BMI in Olanzapine group were significantly higher than those of before treatment and those of Aripiprazole group, with statistically significant differences(P ＜ 0.05). After treatment, triglycerides and alanine aminotransferase in Olanzapine group were significantly higher than those of before treatment, triglycerides in Olanzapine group was higher than that of Aripiprazole group, with statistically significant differences (P ＜ 0.05). The incidence of adverse reactions such as akathisia, tremor, insomnia, excitement or agitation in the Aripiprazole group were high than those of Olanzapine group, with statistically significant differences (P ＜ 0.05). Conclusion Aripiprazole has the same effect as olanzapine. Olanzapine has an effect on blood glucose, lipid metabolism and BMI in patients with schizophrenia. Aripiprazole tends to lead to a higher incidence of partial adverse reactions. In the process of clinical drugs use, individual differences in patients should be aware in the treatment of schizophrenia.

Key words： Schizophrenia Aripiprazole Olanzapine Blood glucose Lipid Body mass index

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Li′na ZHANG Bo YI Qizhong

Cite this article:

ZHANG Li′na ZHANG Bo YI Qizhong. The comparison of effect, blood glucose and lipid metabolism in patients of schizophrenia in the treatment of Aripiprazole and Olanzapine[J]. 中国医药导报, 2017, 14(35): 102-105.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I35/102

[1] 刘克锋，田鑫，薛文华，等.奥氮平对儿童精神分裂症患者糖脂代谢、肝功能及泌乳素的影响[J].重庆医学，2017， 46（9）：1193-1195.
[2] Batmaz M，Bal?觭ik ZE， ?魻zer ?譈，et al. Dandy-Walker Malformation Presenting with Affective Symptoms [J]. Noro Psikiyatr Ars，2017，54（3）：277-281.
[3] 高艳平，董毅，耿峰，等.精神分裂症患者自我怜悯水平及其与快感缺失间的关系[J].中国临床心理学杂志，2016， 24（5）：819-822.
[4] Preskorn SH. CNS Drug Development：Lessons Learned Part 3：Psychiatric and Central Nervous System Drugs Developed Over the Last Decade-Implications for the Field [J]. J Psychiatr Pract，2017，23（5）：352-360.
[5] Zhao S，Zhang Y，Xu L，et al.A Case Report of Psychoactive Drugs Aggravating and Alleviating Meige Syndrome [J]. Shanghai Arch Psychiatry，2016，28（4）：222-226.
[6] 张明园，颜文伟.精神科评定量表专辑[J].上海精神医学，1990，2（增刊）：17-18.
[7] 张文跃，祁小飞，鲍晨曦，等.G蛋白β3亚单位基因多态性与奥氮平所致体重增加的相关性[J].中国神经精神疾病杂志，2016，42（8）：454-459.
[8] Berrios GE，Schioldann J. Motility Psychoses′，by Erik Str?觟mgren（1940）[J]. Hist Psychiatry，2017，28（4）：489-505.
[9] 徐劲节，Dake Q，崔东红.奥氮平致代谢紊乱和心血管疾病研究进展[J].中国神经精神疾病杂志，2016，42（5）：303-306.
[10] 陈方斌，孙剑，阎同军，等.奥氮平、阿立哌唑治疗精神分裂症后肝脏脂肪含量变化及其与胰岛素抵抗的关系[J].中国神经精神疾病杂志，2015，41（11）：646-650.
[11] Uranova NA，Vikhreva OV，Rakhmanova VI，et al. Ultrastructural pathology of oligodendrocytes in the white matter in continuous paranoid schizophrenia：a role for microglia [J]. Zh Nevrol Psikhiatr Im S S Korsakova，2017， 117（9）：76-81.
[12] 廖金敏，阎浩，刘琦，等.精神分裂症患者认知功能受损和阴性症状的关系[J].中国全科医学，2015，18（30）：3666-3670.
[13] Gupta S，Pk P，Gupta R. Necessity of oral health intervention in schizophrenic patients-A review [J]. Nepal J Epidemiol，2016，6（4）：605-612.
[14] 曹阳，康传媛，万帅，等.儿童青少年期起病精神分裂症患者的临床特征与认知功能的关系[J].中国当代儿科杂志，2015，17（4）：379-383.
[15] Kaurav H，Kapoor DN. Implantable systems for drug delivery to the brain [J]. Ther Deliv，2017，8（12）：1097-1107.
[16] 孟宪璋，李挺业.精神分裂症患者与正常人的罗夏测验自我损伤指数[J].中国心理卫生杂志，2015，29（7）：522-527.
[17] Valderrama F，Gómez A，Restrepo D. Isotretinoin Therapy for Acne Vulgaris and First Episode Psychosis in an Adolescent Patient [J]. Rev Colomb Psiquiatr，2017，46（1）：50-54.
[18] 范宁，谭云龙，李佳，等.首发未服药精神分裂症患者血清同型半胱氨酸水平与临床症状的关系[J].中国心理卫生杂志，2015，29（2）：105-108.
[19] 梁军，张向阳.住院精神分裂症患者抗精神病药联合使用合理性的病例分析[J].中国心理卫生杂志，2015，29（1）：47-52.
[20] 张蓓蓓，邓露，国效峰，等.奥氮平导致的血脂变化对精神分裂症患者骨转换生化指标的影响[J].中国骨质疏松杂志，2015，21（7）：846-849.
[21] Hirayasu Y，Sato SI，Shuto N，et al. Efficacy and Safety of Bitopertin in Patients with Schizophrenia and Predominant Negative Symptoms：Subgroup Analysis of Japanese Patients from the Global Randomized Phase 2 Trial [J]. Psychiatry Investi，2017，14（1）：63-73.